Drug Persistence/Adherence in Patients Being Treated With Dabigatran Etexilate or VKA for Stroke Prevention in Non-valvular Atrial Fibrillation (SPAF)
Phase of Trial: Phase IV
Latest Information Update: 20 Apr 2019
Price : $35 *
At a glance
- Drugs Dabigatran etexilate (Primary) ; Phenprocoumon
- Indications Stroke
- Focus Therapeutic Use
- Acronyms SPAF
- Sponsors Boehringer Ingelheim
- 04 Jan 2018 Status changed from active, no longer recruiting to completed.
- 20 Jul 2017 Planned End Date changed from 1 Dec 2016 to 31 Dec 2017.
- 20 Jul 2017 Planned primary completion date changed from 1 Apr 2016 to 31 Dec 2017.